Editas Medicine, Inc. vs Johnson & Johnson — Stock Comparison
Editas Medicine, Inc. (EDIT) and Johnson & Johnson (JNJ) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Johnson & Johnson holds a significant lead over Editas Medicine, Inc. on Q·Score (7.1 vs 4.2 out of 10), led by Quality (9.3 vs 0.2) and Sentiment (6.9 vs 5.4). Analyst consensus targets imply greater upside for EDIT (+114.8%) than for JNJ (+10.7%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
Consensus analyst target of $5.78 is 115% above current price.
⚠ currently unprofitable (-282% margin).
High-quality business with 26% return on equity and 22% profit margins.
⚠ earnings contracting 53% year-over-year.
Analyst Consensus
Fundamentals
Frequently Asked Questions
EDIT vs JNJ: which stock scores better overall?
Based on Q·Score, Johnson & Johnson (JNJ) scores 7.1/10 versus Editas Medicine, Inc. (EDIT) at 4.2/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: EDIT or JNJ?
Johnson & Johnson (JNJ) scores higher on Growth (5.1/10 vs 4.5/10). Editas Medicine, Inc. reports revenue growth (-39.2% YoY) while Johnson & Johnson reports (9.9% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is EDIT or JNJ more attractively valued?
Johnson & Johnson (JNJ) scores higher on Valuation (7.3/10 vs 6.9/10). Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about EDIT vs JNJ?
There are 9 analysts covering EDIT with a consensus price target of $5.78, and 23 analysts covering JNJ with a consensus target of $252.87. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: EDIT or JNJ?
Johnson & Johnson (JNJ) scores higher on Quality (9.3/10 vs 0.2/10). Net profit margin: EDIT at -281.6%, JNJ at 21.8%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: EDIT or JNJ?
Johnson & Johnson (JNJ) scores higher on Financial Health (6.5/10 vs 5.2/10). Market beta: EDIT at 2.10, JNJ at 0.26. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of EDIT and JNJ?
Editas Medicine, Inc. (EDIT) has a market capitalisation of $413M, while Johnson & Johnson (JNJ) has a market cap of $549.8B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do EDIT or JNJ pay dividends?
EDIT does not currently pay a dividend, while JNJ pays a dividend yield of 2.35%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →